It also remains to be investigated whether PtPT is effective in the CML stem cells, which is believed to be a critical cause of imatinib resistance and an obstacle to curing CML. The gene discussed is PTPN2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.